TVTX - Travere Therapeutics, Inc.
NEXT EARNINGS:
Apr 30, 2026
EPS Est: $0.02
|
Rev Est: $139.4M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$42.00
DETAILS
HIGH:
$49.00
LOW:
$35.00
MEDIAN:
$42.00
CONSENSUS:
$42.00
UPSIDE:
36.01%
Market Cap:
2.76B
Volume:
1,283,155
Avg Volume:
2,101,511
52 Week Range:
12.91-42.13
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.81
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
385
IPO Date:
2012-11-08
EPS (TTM):
-0.56
P/E Ratio:
-67.82
Revenue (TTM):
490.73M
Total Assets:
605.19M
Total Debt:
328.73M
Cash & Equiv:
93.03M
Rev Growth (5Y):
19.9%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-14.1%
Debt/Equity:
2.86
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-19 | $0.03 | $0.03 | 0.0% | $129.7M | $132.7M | -2.3% |
| 2025-10-30 | $0.28 | $-0.31 | +190.3% | $164.9M | $147.0M | +12.2% |
| 2025-08-06 | $-0.14 | $-0.28 | +50.0% | $114.4M | $99.5M | +15.0% |
| 2025-05-01 | $-0.47 | $-0.55 | +14.5% | $81.7M | $88.8M | -8.0% |
| 2025-02-20 | $-0.73 | $-0.58 | -25.9% | $74.8M | $72.4M | +3.3% |
| 2024-10-31 | $-0.70 | $-0.70 | 0.0% | $62.9M | $71.4M | -12.0% |
| 2024-08-01 | $-0.90 | $-0.87 | -3.4% | $54.1M | $57.8M | -6.3% |
| 2024-05-06 | $-1.76 | $-0.98 | -79.6% | $41.4M | $42.9M | -3.4% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 490.73M | 233.18M | 145.24M | 109.46M | 131.84M | 198.32M | 175.34M | 164.25M | 154.94M | 133.59M | 99.89M | 28.20M |
| Net Income | (50.26M) | (321.55M) | (111.40M) | (278.48M) | (180.09M) | (169.43M) | (146.43M) | (102.68M) | (59.73M) | (47.90M) | 117.24M | (110.94M) |
| EPS | -0.56 | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 | 3.49 | -4.43 |
| Total Assets | 605.19M | 594.12M | 788.91M | 672.59M | 776.63M | 607.44M | 604.80M | 709.16M | 520.35M | 525.28M | 512.40M | 135.47M |
| Total Debt | 328.73M | 401.58M | 404.78M | 407.49M | 261.99M | 244.03M | 214.87M | 217.55M | 45.08M | 44.42M | 43.90M | 83.77M |
| Cash & Equivalents | 93.03M | 58.53M | 58.18M | 61.69M | 165.75M | 84.77M | 62.44M | 102.87M | 99.39M | 41.00M | 37.80M | 18.20M |
| Operating Cash Flow | 37.78M | (237.47M) | (280.02M) | (186.29M) | (14.79M) | (42.74M) | (58.21M) | (24.96M) | 7.40M | (1.60M) | (554,000) | (45.85M) |
| Free Cash Flow | 37.78M | (338.69M) | (321.61M) | (214.66M) | (38.94M) | (162.59M) | (73.78M) | (44.66M) | (6.61M) | (13.52M) | (7.58M) | (49.81M) |
| FCF per Share | 0.42 | -4.29 | -4.33 | -3.37 | -0.65 | -3.42 | -1.74 | -1.10 | -0.17 | -0.37 | -0.23 | -1.99 |
| Book Value | 114.83M | 59.08M | 200.81M | 42.85M | 302.11M | 211.21M | 221.20M | 318.25M | 293.13M | 307.77M | 299.97M | (37.25M) |
| Cash & ST Investments | 322.80M | 370.70M | 566.85M | 450.25M | 552.88M | 361.59M | 398.52M | 471.54M | 300.63M | 255.87M | 229.60M | 27.76M |
| ROC Equity | -0.44 | -5.44 | -0.55 | -6.50 | -0.60 | -0.80 | -0.66 | -0.32 | -0.20 | -0.16 | 0.39 | N/A |